CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model.

@article{Hassan2011CXCR4PA,
  title={CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model.},
  author={Saima Hassan and Marguerite Buchanan and Kaushar Jahan and Adriana Aguilar-Mahecha and Louis Gaboury and William J. Muller and Yaqoob Alsawafi and Anna Alexeyevna Mourskaia and Peter M Siegel and Ombretta Salvucci and Mark Basik},
  journal={International journal of cancer},
  year={2011},
  volume={129 1},
  pages={225-32}
}
CXCR4 is a chemokine receptor implicated in the homing of cancer cells to target metastatic organs, which overexpress its ligand, stromal cell-derived factor (SDF)-1. To determine the efficacy of targeting CXCR4 on primary tumor growth and metastasis, we used a peptide inhibitor of CXCR4, CTCE-9908, that was administered in a clinically relevant approach using a transgenic breast cancer mouse model. We first performed a dosing experiment of CTCE-9908 in the PyMT mouse model, testing 25, 50 and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 48 extracted citations

Similar Papers

Loading similar papers…